AudioCure
AudioCure Pharma is an innovative clinical-stage pharmaceutical company focused on developing treatments for audiological and neurological disorders with a high unmet medical need.
Our small molecules have shown Proof-of-Principle in preclinical models for a range of otic disorders including hearing loss, tinnitus and electrode insertion trauma as well as Parkinson’s Disease. The safety and tolerability of AudioCure’s lead compound AC102 has been demonstrated in a first-in-human clinical trial. Currently, a Proof-of-Concept, Phase 2 clinical trial evaluating AC102’s efficacy in patients with Sudden Sensorineural Hearing Loss is underway across Europe.
Join us to make a meaningful impact on the lives of those affected by these disorders and turn incurable hearing loss into a treatable event.
